Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
Clearmind Medicine (NASDAQ: CMND) filed a patent application in South Korea covering compositions of its proprietary compound 5-methoxy-2-aminoindane (MEAI) for the treatment of depression on November 5, 2025. The filing is described as strengthening Clearmind’s global IP portfolio for MEAI, a non-hallucinogenic neuroplastogen intended to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without psychedelic effects.
Preclinical studies are reported to show MEAI’s potential to enhance mood regulation and reduce anhedonia. The company says the expanded IP now includes protections across multiple jurisdictions as it prepares for further clinical development and commercialization.
Clearmind Medicine (NASDAQ: CMND) ha depositato una domanda di brevetto in Corea del Sud riguardante le formulazioni del suo composto proprietario 5-metossi-2-amminoindano (MEAI) per il trattamento della depressione il 5 novembre 2025. Il deposito è descritto come un rafforzamento del portafoglio IP globale di Clearmind per MEAI, un neuroplastogeno non allucinogeno destinato a modulare le vie della serotonina, promuovere la neuroplasticità e alleviare i sintomi depressivi senza effetti psichedelici.
Si riportano studi preclinici che indicano il potenziale di MEAI nel migliorare la regolazione dell'umore e nel ridurre l'hedonia negativamente associata. L'azienda afferma che la proprietà intellettuale estesa comprende ora protezioni in diverse giurisdizioni mentre si prepara a ulteriori sviluppi clinici e alla commercializzazione.
Clearmind Medicine (NASDAQ: CMND) presentó una solicitud de patente en Corea del Sur que cubre las composiciones de su compuesto propietario 5-metoxi-2-aminoindano (MEAI) para el tratamiento de la depresión el 5 de noviembre de 2025. La presentación se describe como un fortalecimiento de la cartera de PI global de Clearmind para MEAI, un neuroplastógeno no alucinógeno destinado a modular las vías de la serotonina, promover la neuroplasticidad y aliviar los síntomas depresivos sin efectos psicodélicos.
Se reportan estudios preclínicos que muestran el potencial de MEAI para mejorar la regulación del estado de ánimo y reducir la anhedonía. La empresa afirma que la IP ampliada ahora incluye protecciones en múltiples jurisdicciones mientras se prepara para un mayor desarrollo clínico y comercialización.
Clearmind Medicine (NASDAQ: CMND)가 대한민국에서 우울증 치료를 위한 자사 특허 화합물 5-메톡시-2-아미노인다인(MeAI)의 조합물에 대한 특허 출원을 2025년 11월 5일에 제출했습니다. 이 출원은 MEAI에 대한 Clearmind의 글로벌 IP 포트폴리오를 강화하는 것으로 설명되며, 환각성이 없는 신경가소성 촉진제로서 세로토닌 경로를 조절하고, 신경가소성을 촉진하며, 환각 효과 없이 우울 증상을 완화하는 것을 목표로 합니다.
전임상 연구는 MEAI가 기분 조절을 개선하고 무즐거움(무감) 감소에 잠재력이 있음을 보여준다고 보고합니다. 회사는 확장된 IP가 이제 여러 관할권에 걸쳐 보호를 포함하며 추가 임상 개발 및 상용화를 위한 준비를 하고 있다고 말합니다.
Clearmind Medicine (NASDAQ: CMND) a déposé une demande de brevet en Corée du Sud couvrant des compositions de son composé propriétaire 5-méthoxy-2-aminoindane (MEAI) pour le traitement de la dépression le 5 novembre 2025. Le dépôt est décrit comme un renforcement du portefeuille IP mondial de Clearmind pour MEAI, un neuroplastogène non hallucinogène destiné à moduler les voies de la sérotonine, favoriser la neuroplasticité et atténuer les symptômes dépressifs sans effets psychédéliques.
Des études précliniques rapportent le potentiel du MEAI à améliorer la régulation de l'humeur et à diminuer l'anhédonie. L'entreprise précise que les protections IP élargies couvrent désormais plusieurs juridictions alors qu'elle se prépare à de futurs développements cliniques et à la commercialisation.
Clearmind Medicine (NASDAQ: CMND) hat am 5. November 2025 in Südkorea einen Patentantrag eingereicht, der Zusammensetzungen ihrer proprietären Verbindung 5-Methoxy-2-Amin indan (MEAI) zur Behandlung von Depressionen abdeckt. Die Einreichung wird als Stärkung des globalen IP-Portfolios von Clearmind für MEAI beschrieben, einem Neuroplastogen non-halluzinogenen, das darauf abzielt, Serotoninpfade zu modulieren, Neuroplastizität zu fördern und depressive Symptome ohne psychedelische Effekte zu lindern.
Preklinische Studien sollen das Potenzial von MEAI zeigen, die Stimmungsregulation zu verbessern und Anhedonie zu reduzieren. Das Unternehmen erklärt, dass der erweiterte IP-Schutz nun Schutz in mehreren Rechtsordnungen umfasst, während es sich auf weitere klinische Entwicklungen und die Vermarktung vorbereitet.
Clearmind Medicine (NASDAQ: CMND) قدّمت طلب براءة اختراع في كوريا الجنوبية يغطي تراكيب مركّبها المملوك 5-ميثوكسي-2-أمينوأيندان (MEAI) لعلاج الاكتئاب في 5 نوفمبر 2025. ويُوصف الإيداع بأنه تعزيز لمحفظة الملكية الفكرية العالمية لـ Clearmind لـ MEAI، وهو نيروبلاستوجين غير مهلوس يهدف إلى تعديل مسارات السيروتونين، تعزيز المرونة العصبية، وتخفيف الأعراض الاكتئابية دون آثار نفسية.
تفيد الدراسات قبل السريرية بأن MEAI لديه إمكانية لتحسين تنظيم المزاج وتقليل فقدان المتعة. وتؤكد الشركة أن الحماية الموسّعة للملكية الفكرية تشمل الآن حماية عبر عدة ولايات قضائية بينما تستعد لمزيد من التطوير السريري والتسويق.
- Patent application filed in South Korea on November 5, 2025
- Expanded global IP protections for MEAI across multiple jurisdictions
- MEAI described as non-hallucinogenic neuroplastogen targeting serotonin pathways
- Evidence cited is limited to preclinical studies, no clinical efficacy data reported
- Announcement notes company is still preparing for next stages of clinical development
Insights
Patent filing in South Korea strengthens global IP for MEAI as clinical and commercial preparation continues.
Clearmind expands intellectual property coverage by filing a South Korea patent application for compositions containing MEAI, aimed at treating depression. The filing formalizes ownership claims over a non‑hallucinogenic neuroplastogen designed to modulate serotonin pathways and promote neuroplasticity, which supports clinical development and later commercialization steps by reducing freedom‑to‑operate risks in that jurisdiction.
The announcement rests on three explicit facts: the South Korea patent application, prior preclinical study findings that suggest mood and anhedonia benefits, and the WHO statistic that major depressive disorder affects more than 280 million people worldwide. Key dependencies and risks are procedural: the application is a filing, not a grant, and clinical development and regulatory approvals remain necessary before any commercial benefit accrues. The filing does not provide efficacy, safety, or regulatory outcomes.
Monitor the patent prosecution outcomes and timeline, any listed claims scope, and subsequent filings or grants in other jurisdictions; also watch for disclosed clinical trial starts or regulatory interactions, particularly around
Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans
Vancouver, Canada, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in South Korea covering compositions containing its proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.
This filing further strengthens Clearmind’s global intellectual property portfolio for MEAI, a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without the psychoactive effects associated with traditional psychedelics.
According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
Preclinical studies have demonstrated MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants. This patent application further reinforces Clearmind’s robust IP portfolio, which now includes protections across multiple jurisdictions for MEAI’s applications in various mental health and addiction disorders.
“This patent filing marks another important milestone in expanding our IP protection and advancing MEAI as a novel, next-generation treatment for depression,” said Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “As we continue to broaden our global footprint, we are also preparing for the next stages of clinical development and commercialization to potentially bring our non-hallucinogenic neuroplastogen therapies to patients worldwide.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses MEAI’s potential to enhance mood regulation and reduce anhedonia, offering a differentiated therapeutic approach for patients who do not respond to conventional antidepressants, expanding its IP protection, advancing MEAI as a novel, next-generation treatment for depression, broadening its global footprint and the next stages of its clinical development and commercialization. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on November 5, 2025 about MEAI?
How does the South Korea patent filing affect Clearmind's IP portfolio for MEAI (CMND)?
Has Clearmind reported clinical trial results for MEAI (CMND)?
What is MEAI and how is it described by Clearmind (CMND)?
Does the South Korea patent filing mean MEAI is approved for depression treatment (CMND)?
What are Clearmind's next steps for MEAI mentioned in the announcement (CMND)?
